SCHEMBL15510653

SCHEMBL15510653

CCC[C@H](O)[C@H](N)C(=O)NC(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 8/20 0.42
DPP8 Q6V1X1 6/20 0.42
DPP4 P27487 6/20 0.42
DPP9 Q86TI2 6/20 0.42
SLC15A1 P46059 1/20 0.37
HDAC7 Q8WUI4 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
MEN1 O00255 1/20 0.36
FAAH O00519 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
FAP Q12884 1/20 0.36
SPHK1 Q9NYA1 2/20 0.34
EPHX1 P07099 1/20 0.34
METAP1 P53582 1/20 0.33
CTSC P53634 1/20 0.33
GRIK1 P39086 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13829067 0.78 DPP7 (0.56) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL14974240 0.77 METAP2 (0.48) DPP7DPP8DPP4DPP9SLC15A1
Hydrochloric Acid SCHEMBL5218526 0.77 CYP2D6 (0.39) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL13990341 0.75 HDAC7 (0.41) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL10087537 0.75 HDAC7 (0.41) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL21661351 0.74 DPP4 (0.43) DPP7DPP8DPP4DPP9FAP
SCHEMBL21034775 0.74 DPP4 (0.43) DPP7DPP8DPP4DPP9FAP
SCHEMBL13523609 0.74 DPP4 (0.43) DPP7DPP8DPP4DPP9FAP
SCHEMBL15700570 0.74 ALDH1A1 (0.46) DPP7DPP8DPP4DPP9FAP
SCHEMBL20556002 0.73 CHRM1 (0.48) MAPK1GRIK1SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140066488-A1 Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease PURDUE RESEARCH FOUNDATION (US) 2014-03-06 US disclosed
WO-2014036105-A2 INHIBITORS OF MEMAPSIN 2 CLEAVAGE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066488-A1 Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease PSEN2, BACE2, PSEN1 DPP7 527/4885DPP8 971/4885DPP4 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.